Sigilon Therapeutics Current Cash

The latest current cash for SGTX is $20M as of June 2023. That compares with $35M in the prior-year period — down 43.2% year over year. Investors often review this figure alongside Sigilon Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SGTX's current cash moved from $35M to $20M — a 43.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sigilon Therapeutics's operating scale or balance-sheet position.

A current cash figure of $20M for SGTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SGTX's current cash ($20M), review year-over-year change from $35M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Sigilon Therapeutics's current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.